Therapeutic Glaucoma

>

Latest News

Kowa initiates phase 3 safety trial of NCX 470 in Japan
Kowa initiates phase 3 safety trial of NCX 470 in Japan

August 6th 2025

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

First US patient receives Eyetronic glaucoma treatment at Glaucoma Center of San Francisco
First US patient receives Eyetronic glaucoma treatment at Glaucoma Center of San Francisco

July 23rd 2025

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470

July 20th 2025

PolyActiva secures $40 million AUD in Series C funding
PolyActiva secures $40 million AUD in Series C funding

June 14th 2025

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

June 4th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.